Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 74.80% is 18% below its 5-year average of 90.94%, near the low end of its 5-year range (52.83%–624.78%).
As of the fiscal period ended Tuesday, June 30, 2026. 8.93% below its 12-month average of 82.13%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation.
RETURN ON EQUITY (ROE)
74.80%
RETURN ON EQUITY (ROE) AVG TTM
82.13%
RETURN ON EQUITY (ROE) AVG 3Y
83.39%
RETURN ON EQUITY (ROE) AVG 5Y
90.94%
RETURN ON EQUITY (ROE) AVG 10Y
62.64%
RETURN ON EQUITY (ROE) AVG 15Y
49.63%
RETURN ON EQUITY (ROE) AVG 20Y
41.67%
CURRENT VS TTM AVG
-8.93%
CURRENT VS 3Y AVG
-10.30%
CURRENT VS 5Y AVG
-17.75%
CURRENT VS 10Y AVG
+19.41%
CURRENT VS 15Y AVG
+50.73%
CURRENT VS 20Y AVG
+79.51%
SECTOR MEDIAN · HEALTHCARE
13.25%
median of 83 covered companies
CURRENT VS SECTOR MEDIAN
+464.55%
vs the sector median at left
Amgen Inc.
Market Cap
$212.20B
Return on Equity (ROE)
74.80%
TTM Avg
82.13%
3Y Avg
83.39%
5Y Avg
90.94%
Market Cap
$200.54B
Return on Equity (ROE)
53.50%
TTM Avg
61.58%
3Y Avg
67.05%
5Y Avg
123.42%
Market Cap
$224.09B
Return on Equity (ROE)
13.25%
TTM Avg
12.70%
3Y Avg
13.51%
5Y Avg
15.24%
Market Cap
$182.59B
Return on Equity (ROE)
10.61%
TTM Avg
20.32%
3Y Avg
18.59%
5Y Avg
17.97%
Market Cap
$182.06B
Return on Equity (ROE)
-27.39%
TTM Avg
19.98%
3Y Avg
21.60%
5Y Avg
19.44%
Market Cap
$248.20B
Return on Equity (ROE)
20.79%
TTM Avg
19.16%
3Y Avg
15.60%
5Y Avg
13.86%
Market Cap
$158.39B
Return on Equity (ROE)
5.09%
TTM Avg
9.04%
3Y Avg
13.32%
5Y Avg
16.07%
Market Cap
$144.25B
Return on Equity (ROE)
7.61%
TTM Avg
7.38%
3Y Avg
9.51%
5Y Avg
10.24%
Market Cap
$134.24B
Return on Equity (ROE)
21.76%
TTM Avg
8.96%
3Y Avg
15.60%
5Y Avg
19.47%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Amgen Inc. (AMGN) | $212.20B | 74.80% | 82.13% | 83.39% | 90.94% |
| Novo Nordisk A/S (NVO)vs › | $200.54B | 53.50% | 61.58% | 67.05% | 123.42% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $224.09B | 13.25% | 12.70% | 13.51% | 15.24% |
| Abbott Laboratories (ABT)vs › | $182.59B | 10.61% | 20.32% | 18.59% | 17.97% |
| Gilead Sciences, Inc. (GILD)vs › | $182.06B | -27.39% | 19.98% | 21.60% | 19.44% |
| AstraZeneca PLC (AZN)vs › | $248.20B | 20.79% | 19.16% | 15.60% | 13.86% |
| Pfizer Inc. (PFE)vs › | $158.39B | 5.09% | 9.04% | 13.32% | 16.07% |
| Danaher Corporation (DHR)vs › | $144.25B | 7.61% | 7.38% | 9.51% | 10.24% |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $134.24B | 21.76% | 8.96% | 15.60% | 19.47% |
| Bristol-Myers Squibb Company (BMY)vs › | $132.14B | 41.59% | -8.30% | 7.76% | 4.45% |
ROE
74.8%
ROA
9.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 74.80% |
| 2026-03-31 | 84.87% |
| 2025-12-31 | 89.06% |
| 2025-09-30 | 72.82% |
| 2025-06-30 | 89.11% |
| 2025-03-31 | 95.59% |
| 2024-12-31 | 69.59% |
| 2024-09-30 | 56.20% |
| 2024-06-30 | 52.83% |
| 2024-03-31 | 74.93% |
| 2023-12-31 | 107.78% |
| 2023-09-30 | 98.82% |
| 2023-06-30 | 117.67% |
| 2023-03-31 | 148.04% |
| 2022-12-31 | 178.97% |
| 2022-09-30 | 187.11% |
| 2022-06-30 | 271.85% |
| 2022-03-31 | 624.78% |
| 2021-12-31 | 87.96% |
| 2021-09-30 | 68.26% |
| 2021-06-30 | 69.67% |
| 2021-03-31 | 75.91% |
| 2020-12-31 | 77.20% |
| 2020-09-30 | 67.09% |
| 2020-06-30 | 68.48% |
| 2020-03-31 | 80.92% |
| 2019-12-31 | 81.07% |
| 2019-09-30 | 73.83% |
| 2019-06-30 | 73.73% |
| 2019-03-31 | 74.55% |
| 2018-12-31 | 67.15% |
| 2018-09-30 | 15.35% |
| 2018-06-30 | 15.86% |
| 2018-03-31 | 14.21% |
| 2017-12-31 | 7.84% |
| 2017-09-30 | 25.37% |
| 2017-06-30 | 25.77% |
| 2017-03-31 | 25.76% |
| 2016-12-31 | 25.85% |
| 2016-09-30 | 24.65% |
| 2016-06-30 | 24.67% |
| 2016-03-31 | 25.16% |
| 2015-12-31 | 24.71% |
| 2015-09-30 | 23.00% |
| 2015-06-30 | 21.15% |
| 2015-03-31 | 21.53% |
| 2014-12-31 | 20.01% |
| 2014-09-30 | 19.29% |
| 2014-06-30 | 20.54% |
| 2014-03-31 | 20.76% |
| 2013-12-31 | 23.00% |
| 2013-09-30 | 22.31% |
| 2013-06-30 | 22.27% |
| 2013-03-31 | 23.57% |
| 2012-12-31 | 22.80% |
| 2012-09-30 | 22.57% |
| 2012-06-30 | 19.95% |
| 2012-03-31 | 19.83% |
| 2011-12-31 | 19.35% |
| 2011-09-30 | 16.01% |
| 2011-06-30 | 17.78% |
| 2011-03-31 | 18.35% |
| 2010-12-31 | 19.32% |
| 2010-09-30 | 18.84% |
| 2010-06-30 | 20.22% |
| 2010-03-31 | 21.28% |
| 2009-12-31 | 20.32% |
| 2009-09-30 | 20.28% |
| 2009-06-30 | 20.63% |
| 2009-03-31 | 20.43% |
| 2008-12-31 | 20.58% |
| 2008-09-30 | 20.52% |
| 2008-06-30 | 16.80% |
| 2008-03-31 | 16.72% |
| 2007-12-31 | 17.72% |
| 2007-09-30 | 18.72% |
| 2007-06-30 | 24.68% |
| 2007-03-31 | 15.52% |
| 2006-12-31 | 15.56% |
| 2006-09-30 | 16.60% |
| 2006-06-30 | 16.66% |
| 2006-03-31 | 21.97% |
| 2005-12-31 | 17.96% |
| 2005-09-30 | 17.24% |
| 2005-06-30 | 14.34% |
| 2005-03-31 | 13.27% |
| 2004-12-31 | 11.99% |
| 2004-09-30 | 11.21% |
| 2004-06-30 | 13.38% |
| 2004-03-31 | 12.55% |
| 2003-12-31 | 11.65% |
| 2003-09-30 | 11.15% |
| 2003-06-30 | -5.51% |
